Oncoceutics Inc. announced results from the first cohort of its phase II trial for patients with recurrent glioblastoma, which showed median overall survival in the first cohort of 17 patients two times that indicated in the current GBM patient literature.
Tocagen Inc. expanded its phase II/III clinical trial Toca 5, and is now enrolling patients in Canada. The trial first began enrolling patients in the U.S. in December 2015.
A phase III trial of Tumor Treating Fields was terminated early following early success detailed in an interim analysis. The trial evaluated patients with newly diagnosed glioblastoma being treated with the NovoTTF-100A System, developed by Novocure, in combination with standard-of-care temozolomide.
A dendritic cell-based immunotherapeutic vaccine increased median overall survival by about four months in a phase II placebo-controlled study in newly diagnosed glioblastoma multiforme.
A phase III study of Avastin failed to increase overall survival or statistically significant progression-free survival for glioblastoma patients in the frontline setting. The international study was a collaboration among the cooperative groups RTOG, NCCTG, and ECOG.
